Navigation Links
As Type 2 Diabetes Grows at Alarming Rates, Pharmaceutical Companies Will Face New Challenges and New Opportunities

FARMINGTON, Conn., Feb. 6, 2013 /PRNewswire-iReach/ -- Despite modern science's best efforts, the most common type of diabetes - Type 2 - is reaching epidemic levels across the world. The economic consequences of this growth are vast, involving not only the direct burden of managing the disease itself but also its common - often catastrophic - complications. Although more than 40 therapeutics are approved for type 2 diabetes, there are high levels of unmet need, creating opportunities for companies in the secondary and tertiary treatment segments that address such complications as cardiovascular disease, peripheral neuropathy, and blindness. These trends are of great concern, not only to the individuals affected, but also to governments and providers of health care.


Global Information (GII) provides the latest market insight and research on business opportunities within the diabetes market. Preview a selection of GII's most recently added reports below:

Global Markets for Diabetes Therapeutics and Diagnostics

The aim of this report is to provide detailed market, technology, and industry analyses to help readers quantify and qualify the market for drugs used in the treatment of diabetes and for devices and instruments used in the diagnosis and monitoring of diabetes.

This report discusses the implications of the above-mentioned trends in the context of the current size and growth of the diabetes market, discussed both in global terms and in terms of the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on merger and acquisition (M&A) activity. Five-year global sales forecasts are provided for main drug and device categories, and breakdowns are provided for several national markets.

An Executive Summary for this report and free sample pages from the full document are available at

Request free samples pages from Global Markets for Diabetes Therapeutics and Diagnostics -- Focus on Asia:

Request free samples pages from Global Markets for Diabetes Therapeutics and Diagnostics -- Focus on Europe:

Diabetes Therapeutics Market in India to 2018

With approximately 61.3 million diabetics in 2011, India presents a promising opportunity for pharmaceutical companies with anti-diabetic product portfolios. India, after China, is the second diabetes capital of the world. A growing patient population and increased demand for effective medication are offering both domestic and Multinational Companies (MNCs) promising opportunities.

MNCs rising interest in the emerging markets is indicated by the joint venture between Sun Pharma and Merck to bring new anti-diabetics to emerging markets, the USV-Novartis collaboration for the marketing of Galvus, the Lupin-Eli Lilly alliance for the marketing of insulin, and collaborations between Eli Lilly and Boehringer Ingelheim.

Through strategic consolidations such as these, MNCs are trying to expand their patient base by widening their reach in the domestic market. More aggressive marketing and a wider reach could potentially increase their market share and also develop a platform from which to ensure R&D success in terms of pipeline products. Strategic collaborations would help MNCs to market their products throughout India and overturn the competition in the established markets. They would also help domestic companies as having a MNC with sufficient resources in place on their side means strong sales forces and manufacturing capabilities. Given the large market and predicted double-digit growth rate, more strategic consolidations are expected to follow during the forecast period.

An Executive Summary for this report and free sample pages from the full document are available at

Diabetes Partnering 2007-2012

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

This data driven report contains over 500 links to online copies of actual diabetes deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors diabetes technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

An Executive Summary for this report and free sample pages from the full document are available at

For more market research highlights, technical research news and industry updates, please visit

About Global Information Inc. Global Information (GII) ( is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.

Media Contact: Jeremy Palaia Global Information, Inc., 1-860-674-8796,

News distributed by PR Newswire iReach:

SOURCE Global Information, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Tandem Diabetes Care Acquires Select Patents and Patent Applications from Smiths Medical
2. Pharmaceutical Company Achieves Positive In-Vitro Testing Results Diabetes Drug
3. In Preventing Diabetes-Related Heart Disease, Blood Pressure and Cholesterol Targets are Higher Priorities than Blood Sugar
4. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
5. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
6. Genalyte Awarded $500,000 SBIR Grant To Develop Multiplexed Assays For Early Detection And Monitoring Of Type 1 Diabetes
7. ObeTherapy Announces the Publication of Results Obtained with one of its Lead Compounds on a New Target for the Treatment of Obesity and Type II Diabetes
8. High Degree of Disease Prevalence Sustains Diabetes Diagnostics Market in Europe, Finds Frost & Sullivan
9. Novo Nordisk Supports Four San Francisco-based Organizations In Fight Against Diabetes
10. LEVEL Lifes "FUEL A Cure" Diabetes Contest
11. Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015  Athletic apparel ... founder have agreed to pay $1.35 million to ... advertised the company,s copper-infused compression clothing would relieve ... arthritis and other diseases. Tommie ... requires the company and its founder and chairman ...
(Date:12/1/2015)... de diciembre de 2015  AccuTEC Blades, ... de precisión, develó hoy un nuevo logo ... marca. El nuevo logo destaca la experiencia ... ingeniería de productos con cuchillas donde "el ... --> ...
(Date:12/1/2015)... --> --> ... Acid Labeling Market by Product (Reagents & Kits, Services), ... Vitro Transcription, Reverse Transcription, End Labeling), by Region - ... market is expected to reach USD 1,925.7 Million by ... a CAGR of 8.65%. Browse 77 market ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... ... must mark the film for accurate interpretation by the radiologist. The marking utensils ... inventor from Sacramento, Calif., has found a way to alleviate this problem. , ...
(Date:12/1/2015)... ... December 01, 2015 , ... Visage accelerates mobile ... wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced they are ... of North America (RSNA) 2015 annual meeting through December 3 in Chicago, Illinois, ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... it has been selected as a finalist in this year’s Fierce Innovation Awards: ... Next IT Healthcare was recognized as a finalist in the category of Digital ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic and ... to the devices for sale in the United States. Clarity is a Superior ... nm Nd:YAG lasers, into a single platform that is easy to own and operate. ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Effective Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning ... results, once a deal is signed. This quick-read guidance suggests that failing ...
Breaking Medicine News(10 mins):